RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.
about
Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled AnalysisComparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report.Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin.
P2860
RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RECIST 1.1 and serum thyroglob ...... ferentiated thyroid carcinoma.
@en
RECIST 1.1 and serum thyroglob ...... ferentiated thyroid carcinoma.
@nl
type
label
RECIST 1.1 and serum thyroglob ...... ferentiated thyroid carcinoma.
@en
RECIST 1.1 and serum thyroglob ...... ferentiated thyroid carcinoma.
@nl
prefLabel
RECIST 1.1 and serum thyroglob ...... ferentiated thyroid carcinoma.
@en
RECIST 1.1 and serum thyroglob ...... ferentiated thyroid carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
RECIST 1.1 and serum thyroglob ...... ferentiated thyroid carcinoma.
@en
P2093
P2860
P304
P356
10.3892/OL.2013.1424
P577
2013-06-25T00:00:00Z